Synthesis and biological evaluation of novel N₁-phenylsulphonyl indole derivatives as potent and selective 5-HT₆R ligands for the treatment of cognitive disorders

References

• Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64–78
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005;43:442–9
   PubMed Web of Science ®Google Scholar
• Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurol 2009;72:1555–61
   PubMed Web of Science ®Google Scholar
• Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388–97
   PubMed Web of Science ®Google Scholar
• Van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009;5:237–47
   PubMed Web of Science ®Google Scholar
• Gerard C, Martres MP, Lefevre K, et al. Immunolocalization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 1997;746:207–19
   PubMed Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacol 2001;25:662–8
   PubMed Web of Science ®Google Scholar
• Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006;553:109–19
   PubMed Web of Science ®Google Scholar
• Ramirez MJ, Lai MKP, Tordera RM, Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs 2014;74:729–36
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kambhampati R, Shinde A, et al. Alzheimer’s and dementia. International conference on Alzheimer’s Disease, Vienna. 2009;5:250
   Google Scholar
• Biotie therapies. Available from: http://www.biotie.com/en/product_and_development/development_pipeline/syn120 [last accessed 1 May 2015]
   Google Scholar
• Pfizer. Available from: http://www.pfizer.com/sites/default/files/productpipeline/pipeline_2013_0509.pdf/Neuroscience & pain [last accessed 1 May 2015]
   Google Scholar
• Avineuro Pharmaceuticals. Available from: http://www.biocentury.com/products/avn-211 [last accessed 1 May 2015]
   Google Scholar
• (a) Lundbeck. Available from: http://www.lundbeck.com/global [last accessed 1 May 2015]. (b) Jorn A, Benny B, Ben G, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010;13:1021–33
   Google Scholar
• GlaxoSmithKline. Available from: http://www.gsk.com/research/our-product-pipeline.html [last accessed 1 May 2015]
   Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Synthesis and structure−activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT6 receptor (5-HT6R) antagonists. J Med Chem 2011;54:8161–73
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Dmitriev DE, Golovina ES, et al. (3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor. J Med Chem 2010;53:5186–96
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Antagonists of 5-HT6 receptors. Substituted 3-(phenylsulfonyl) pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl) pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines—Synthesis and ‘structure–activity’ relationship. Bioorg Med Chem Lett 2012;22:4273–80
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, et al. Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists. Bioorg Med Chem 2011;19:1482–91
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, et al. 2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists. Eur J Med Chem 2011;46:1189–97
   PubMed Web of Science ®Google Scholar
• (a) Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;4:2795–812. (b) Glennon RA, Lee M, Rangisetty JB, et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem 2000;43:1011–18
   Google Scholar
• Liu KG, Robichaud AJ, Bernotas RC, et al. 5Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem 2010;53:7639–46
   PubMed Web of Science ®Google Scholar
• Routledge C, Bromidge SM, Moss SF, et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol 2000;130:1606–12
   PubMed Web of Science ®Google Scholar
• Bromidge SM, Brown AM, Clarke SE, et al. 5Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J Med Chem 1999;42:202–5
   PubMed Web of Science ®Google Scholar
• Johnson CN, Ahmed M, Miller ND. 5HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel 2008;11:642–54
   PubMedGoogle Scholar
• Cole DC, Lennox WJ, Stock JR, et al. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2005;15:4780–5
   PubMed Web of Science ®Google Scholar
• Cole DC, Ellingboe JW, Lennox WJ, et al. N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2005;15:379–83
   PubMed Web of Science ®Google Scholar
• (a) Cole DC, Lennox WJ, Lombardi S, et al. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem 2005;48(2):353–6. (b) Liu KG, Robichaud A. 5HT6 antagonists as potential treatment for cognitive dysfunction. J Drug Dev Res 2009;70:145–68. (c) Beard CC, Clark RD, Fisher LM, et al. US Patent 0073700 A1; 2003
   Google Scholar
• Benhamú B, Martín-Fontecha M, Vázquez-Villa H, et al. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. J Med Chem 2014;57:7160–81
   PubMed Web of Science ®Google Scholar
• Nirogi R, Daulatabad A, Parandhama G, et al. Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT(6) receptor antagonists. Bioorg Med Chem Lett 2010;20:4440–3
   PubMed Web of Science ®Google Scholar
• Nirogi R, Dwarampudi A, Kambhampati R, et al. Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands. Bioorg Med Chem Lett 2011;21:4577–80
   PubMed Web of Science ®Google Scholar
• Nirogi R, Deshpande A, Kambhampati R, et al. Indole-3-piperazinyl derivatives: novel chemical class of 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2011;21:346–9
   PubMed Web of Science ®Google Scholar
• (a) Nirogi R, Kothmirkar P, Kambhampati R, et al. Novel and potent 5-piperazinyl methyl-N1-aryl sulfonyl indolederivatives as 5-HT6 receptor ligands. ACS Med Chem Lett 2010;1:340–4. (b) Nirogi R, Badange R, Kambhampati R, et al. Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands. Bioorg Med Chem Lett 2012;22:7431–5. (C) Ramakrishna VSN, Shirsath VS, Kambhampati RS, et al. Narylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them. WO 2004/048330 A1; 2004
   Google Scholar
• Ivachtchenko A, Golovina E, Kadieva M, et al. Synthesis of substituted diphenyl sulfones and their structure-activity relationship with the antagonism of 5-НТ6 receptors. Bioorg Med Chem 2013;21:4614–27
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Benhamu B, Fuente T, et al. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J Med Chem 2005;48:4216–19
   PubMed Web of Science ®Google Scholar
• Bromidge SM. Potent and selective 5-HT6 receptor antagonists. Spec Publ – R Soc Chem 2001;264:101–19
   Google Scholar
• Hirst WD, Minton JA, Bromidge SM, et al. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000;130:1597–605
   PubMed Web of Science ®Google Scholar
• Pullagurla MR, Westkaemper RB, Glennon RA. Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett 2004;14:4569–73
   PubMed Web of Science ®Google Scholar
• Dukat M, Mosier PD, Kolanos R, et al. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin eceptors: receptor modeling studies. J Med Chem 2008;51:603–11
   PubMed Web of Science ®Google Scholar
• Sikazwe D, Bondarev ML, Dukat M, et al. Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem 2006;49:5217–25
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;17:207–31
   Web of Science ®Google Scholar
• Ivachtchenko A, Dmitriev D, Golovina E, et al. Synthesis of cycloalkane-annelated 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines and their evaluation as 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2010;20:2133–6
   PubMed Web of Science ®Google Scholar
• Kohen R, Fashingbauer LA, Heidmann DE, et al. Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Res Mol Brain Res 2001;90:110–17
   PubMedGoogle Scholar
• Gonzalo R, Elisabeth S, Marta P, et al. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol 2006;148:1133–43
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Cytochromes P. Structure, function and mechanism. London: Taylor and Francis Publishing; 1996
   Google Scholar
• Ennaceur A, Neave N, Aggleton JP. The effects of neurotoxic lesions of the perirhinal cortex combined to fornix transection on object recognition memory in the rat. Behav Brain Res 1997;88:181–93
   PubMed Web of Science ®Google Scholar